Venous thromboembolism is a possible fatal complication after pelvic surgery. There is a lack of trials assessing the effect of prophylactic measures in urology. The aim of the study was to evaluate the practice of thrombosis prophylaxis in a Central European country. A questionnaire of performed radical prostatectomies, way of thrombosis prophylaxis and number of experienced thrombotic events was posted to all departments of urology in Hungary. With a response rate of 59%, 506 radical prostatectomies were reported. Low molecular weight heparin was administered by 100% of the departments. Graduated support stockings were applied by 37% of the patients. Early mobilization was the most common form of mechanic prophylaxis (57%). Thrombotic events were experienced in 1.4%, 0.2% were fatal. The thrombosis prophylaxis of patients undergoing radical prostatectomy is not unified. Due to the potential mortality of thrombotic complications it should be evaluated and prophylaxis should be recommended in urological guidelines.

1.
Phillips J, Makarawo T, Abedin A, Eaton J, Makar A: Extended venous thromboembolism prophylaxis after radical pelvic surgery for urological cancers. BJU Int 2010;106:1110-1111.
2.
Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, Moia M, Parazzini F, Rossi R, Sonaglia F, Valarani B, Bianchini C, Gussoni G: A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006;243:89-95.
3.
American Urological Association (AUA): Best Practice Policy Statement for the Prevention of Deep Vein Thrombosis in Patients Undergoing Urologic Surgery. Linthicum/MD, AUA, 2008, pp 1-29.
4.
Galvin DJ, Mulvin D, Quinlan DM: Thromboprophylaxis for radical prostatectomy: a comparative analysis of present practice between the USA, the UK, and Ireland. Prostate 2004;60:338-342.
5.
Parsons KF, Fall M, Irani J, Llorente C, N'Dow JNO, Sylvester RJ, Van Poppel H: EAU Guidelines 2013. www.uroweb.org.
6.
Bigg SW, Catalona WJ: Prophylactic mini-dose heparin in patients undergoing radical retropubic prostatectomy. A prospective trial. Urology 1992;39:309-313.
7.
Hansberry KL, Thompson IM Jr, Bauman J, Deppe S, Rodriguez FR: A prospective comparison of thromboembolic stockings, external sequential pneumatic compression stockings and heparin-sodium/dihydroergotamine mesylate for the prevention of thromboembolic complications in urological surgery. J Urol 1991;145:1205-1208.
8.
Maxwell GL, Myers ER, Clarke-Pearson DL: Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery. Obstet Gynecol 2000;95:206-214.
9.
Geerts WH, Pineo GF, Heit JA, Bergquist D, Lassen MR, Colwell CW, Ray JG: Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338S-400S.
10.
Benyo M, Flasko T, Molnar ZS, Kerenyi A, Batta Z, Jozsa T, Harsfalvi J: Follow-up of thrombin generation after prostate cancer surgery: global test for increased hypercoagulability. PLoS One 2012;12:e51299.
11.
Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, Guazzoni G, Guillonneau B, Menon M, Montorsi F, Patel V, Rassweiler J, Van Poppel H: Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 2009;55:1037-1063.
12.
Froehner M, Koch R, Leike S, Novotny V, Twelker R, Wirth MP: Urinary tract-related quality of life after radical prostatectomy: open retropubic versus robot-assisted laparoscopic approach. Urol Int 2013;90:36-40.
13.
Urakami S, Yonese J, Yamamoto S, Yuasa T, Kitsukawa S, Numao N, Kubo Y, Ito M, Sukegawa G, Yasuda Y, Ishikawa Y, Fukui I: Outcome of antegrade radical prostatectomy with intended wide resection in prostate cancer patients with a preoperative serum PSA level >100 ng/ml. Urol Int 2011;87:175-181.
14.
Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R: Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e326S-e350S.
15.
Albaladejo P, Samama CM: Patients under anti-platelet therapy. Best Pract Res Clin Anaesthesiol 2010;24:41-50.
16.
Wang J, Zhan C, Tan G, Chen W, Yang B, Tan D: Risk of bleeding complications after preoperative antiplatelet withdrawal versus continuing antiplatelet drugs during transurethral resection of the prostate and prostate puncture biopsy: a systematic review and meta-analysis. Urol Int 2012;89:433-438.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.